Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care
PharmacoEconomics · 2024
DOI: 10.1007/s40273-024-01430-7 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PharmacoEconomics, 2024. Verfasst von Amy Gye und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, New South Wales, Australia. amy.gye@student.uts.edu.au. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Quality-Adjusted Life Years, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Immunotherapy, Adoptive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Australia, University of Technology Sydney.
Abstract (Originalsprache)
OBJECTIVE: Chimeric antigen-receptor T-cell therapy (CAR-T) is characterised by early phase data at the time of registration, high upfront cost and a complex manufacturing and administration process compared with standard therapies. Our objective was to compare the performance of different models to assess the cost effectiveness of CAR-T using a state-transition model (STM), partitioned survival model (PSM) and discrete event simulation (DES). METHODS: Individual data for tisagenlecleucel for the treatment of young patients with acute lymphoblastic leukaemia (ALL) were used to populate the models. Costs and benefits were measured over a lifetime to generate a cost per quality-adjusted life-year (QALY). Model performance was compared quantitatively on the outcomes generated and a checklist developed summarising the components captured by each model type relevant to assessing cost effectiveness of CAR-T. RESULTS: Models generated similar results with base-case analyses ranging from an incremental cost per QALY of $96,074-$99,625. DES was the only model to specifically capture CAR-T wait time, demonstrating a substantial loss of benefit of CAR-T with increased wait time. CONCLUSION: Although model type did not meaningfully impact base-case results, the ability to incorporate an outcome-based payment arrangement (OBA) and wait time are important elements to consider when selecting a model for CAR-T. DES provided greater flexibility compared with STM and PSM approaches to deal with the complex manufacturing and administration process that can lead to extended wait times and substantially reduce the benefit of CAR-T. This is an important consideration when selecting a model type for CAR-T, so major drivers of uncertainty are considered in funding decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, New South Wales, Australia. amy.gye@student.uts.edu.au.
- Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Amy Gye
Förderung
- Novartis Australia
- University of Technology Sydney
Zitieren
APA
Gye, A., De Abreu Lourenco, R., & Goodall, S. (2024). Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care. PharmacoEconomics. https://doi.org/10.1007/s40273-024-01430-7
Vancouver
Gye A, De Abreu Lourenco R, Goodall S. Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care. PharmacoEconomics. 2024. doi:10.1007/s40273-024-01430-7
BibTeX
@article{Gye2024,
author = {Gye, Amy and De Abreu Lourenco, Richard and Goodall, Stephen},
title = {Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care},
journal = {PharmacoEconomics},
year = {2024},
doi = {10.1007/s40273-024-01430-7}
}
EUVIMED